Phosphodiesterase  ||| S:0 E:18 ||| NNP
Type  ||| S:18 E:23 ||| NNP
5  ||| S:23 E:25 ||| CD
Inhibitor  ||| S:25 E:35 ||| NNP
Use  ||| S:35 E:39 ||| NNP
Following  ||| S:39 E:49 ||| NNP
Radical  ||| S:49 E:57 ||| NNP
Prostatectomy  ||| S:57 E:71 ||| NNP
is  ||| S:71 E:74 ||| VBZ
not  ||| S:74 E:78 ||| RB
Associated  ||| S:78 E:89 ||| NNP
with  ||| S:89 E:94 ||| IN
an  ||| S:94 E:97 ||| DT
Increased  ||| S:97 E:107 ||| JJ
Risk  ||| S:107 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
Biochemical  ||| S:115 E:127 ||| NNP
Recurrence  ||| S:127 E:138 ||| NNP
Recently ||| S:138 E:146 ||| NNP
,  ||| S:146 E:148 ||| ,
conflicting  ||| S:148 E:160 ||| JJ
findings  ||| S:160 E:169 ||| NNS
have  ||| S:169 E:174 ||| VBP
been  ||| S:174 E:179 ||| VBN
reported  ||| S:179 E:188 ||| VBN
on  ||| S:188 E:191 ||| IN
the  ||| S:191 E:195 ||| DT
effect  ||| S:195 E:202 ||| NN
of  ||| S:202 E:205 ||| IN
phosphodiesterase  ||| S:205 E:223 ||| JJ
type  ||| S:223 E:228 ||| NN
5  ||| S:228 E:230 ||| CD
inhibitor  ||| S:230 E:240 ||| NNS
( ||| S:240 E:241 ||| -LRB-
PDE5I ||| S:241 E:246 ||| NNP
)  ||| S:246 E:248 ||| -RRB-
use  ||| S:248 E:252 ||| NN
on  ||| S:252 E:255 ||| IN
biochemical  ||| S:255 E:267 ||| JJ
outcome  ||| S:267 E:275 ||| NN
following  ||| S:275 E:285 ||| VBG
radical  ||| S:285 E:293 ||| JJ
prostatectomy  ||| S:293 E:307 ||| NNS
( ||| S:307 E:308 ||| -LRB-
RP ||| S:308 E:310 ||| NNP
) ||| S:310 E:311 ||| -RRB-
.  ||| S:311 E:313 ||| .
Thus ||| S:313 E:317 ||| RB
,  ||| S:317 E:319 ||| ,
we  ||| S:319 E:322 ||| PRP
investigated  ||| S:322 E:335 ||| VBD
the  ||| S:335 E:339 ||| DT
impact  ||| S:339 E:346 ||| NN
of  ||| S:346 E:349 ||| IN
PDE5I  ||| S:349 E:355 ||| CD
treatment  ||| S:355 E:365 ||| NN
following  ||| S:365 E:375 ||| VBG
RP ||| S:375 E:377 ||| NNP
,  ||| S:377 E:379 ||| ,
including  ||| S:379 E:389 ||| VBG
therapeutic  ||| S:389 E:401 ||| JJ
strategy ||| S:401 E:409 ||| NN
,  ||| S:409 E:411 ||| ,
timing ||| S:411 E:417 ||| NN
,  ||| S:417 E:419 ||| ,
duration ||| S:419 E:427 ||| NN
,  ||| S:427 E:429 ||| ,
and  ||| S:429 E:433 ||| CC
drug  ||| S:433 E:438 ||| NN
type ||| S:438 E:442 ||| NN
,  ||| S:442 E:444 ||| ,
on  ||| S:444 E:447 ||| IN
oncologic  ||| S:447 E:457 ||| JJ
outcomes ||| S:457 E:465 ||| NNS
.  ||| S:465 E:467 ||| .
We  ||| S:467 E:470 ||| PRP
analyzed  ||| S:470 E:479 ||| VBD
records  ||| S:479 E:487 ||| NNS
of  ||| S:487 E:490 ||| IN
1082  ||| S:490 E:495 ||| CD
patients  ||| S:495 E:504 ||| NNS
who  ||| S:504 E:508 ||| WP
underwent  ||| S:508 E:518 ||| VBD
bilateral  ||| S:518 E:528 ||| JJ
nerve-sparing  ||| S:528 E:542 ||| JJ
RP  ||| S:542 E:545 ||| NN
for  ||| S:545 E:549 ||| IN
clinically  ||| S:549 E:560 ||| JJ
localized  ||| S:560 E:570 ||| JJ
prostate  ||| S:570 E:579 ||| JJ
cancer  ||| S:579 E:586 ||| NN
( ||| S:586 E:587 ||| -LRB-
PCa ||| S:587 E:590 ||| NNP
)  ||| S:590 E:592 ||| -RRB-
between  ||| S:592 E:600 ||| IN
2005  ||| S:600 E:605 ||| CD
and  ||| S:605 E:609 ||| CC
2014 ||| S:609 E:613 ||| CD
.  ||| S:613 E:615 ||| .
Patients  ||| S:615 E:624 ||| NNS
were  ||| S:624 E:629 ||| VBD
categorized  ||| S:629 E:641 ||| VBN
according  ||| S:641 E:651 ||| VBG
to  ||| S:651 E:654 ||| TO
PDE5I  ||| S:654 E:660 ||| CD
use  ||| S:660 E:664 ||| NN
within  ||| S:664 E:671 ||| IN
2 years  ||| S:671 E:679 ||| CD
following  ||| S:679 E:689 ||| VBG
RP ||| S:689 E:691 ||| NNP
:  ||| S:691 E:693 ||| :
non-user ||| S:693 E:701 ||| NN
,  ||| S:701 E:703 ||| ,
on-demand ||| S:703 E:712 ||| NNP
,  ||| S:712 E:714 ||| ,
and  ||| S:714 E:718 ||| CC
rehabilitation  ||| S:718 E:733 ||| NN
( ||| S:733 E:734 ||| -LRB-
daily  ||| S:734 E:740 ||| JJ
PDE5I  ||| S:740 E:746 ||| CD
use  ||| S:746 E:750 ||| NN
for  ||| S:750 E:754 ||| IN
≥3 months ||| S:754 E:763 ||| CD
)  ||| S:763 E:765 ||| -RRB-
groups ||| S:765 E:771 ||| NNS
.  ||| S:771 E:773 ||| .
Associations  ||| S:773 E:786 ||| NNS
of  ||| S:786 E:789 ||| IN
various  ||| S:789 E:797 ||| JJ
factors  ||| S:797 E:805 ||| NNS
with  ||| S:805 E:810 ||| IN
biochemical  ||| S:810 E:822 ||| JJ
recurrence  ||| S:822 E:833 ||| NN
( ||| S:833 E:834 ||| -LRB-
BCR ||| S:834 E:837 ||| NNP
)  ||| S:837 E:839 ||| -RRB-
were  ||| S:839 E:844 ||| VBD
analyzed  ||| S:844 E:853 ||| VBN
using  ||| S:853 E:859 ||| VBG
a  ||| S:859 E:861 ||| DT
Cox  ||| S:861 E:865 ||| NNP
multivariate  ||| S:865 E:878 ||| FW
proportional  ||| S:878 E:891 ||| FW
hazards  ||| S:891 E:899 ||| FW
model ||| S:899 E:904 ||| NN
.  ||| S:904 E:906 ||| .
Propensity  ||| S:906 E:917 ||| JJ
score-matched  ||| S:917 E:931 ||| JJ
analysis  ||| S:931 E:940 ||| NN
was  ||| S:940 E:944 ||| VBD
also  ||| S:944 E:949 ||| RB
performed ||| S:949 E:958 ||| VBN
.  ||| S:958 E:960 ||| .
Among  ||| S:960 E:966 ||| IN
the  ||| S:966 E:970 ||| DT
subjects  ||| S:970 E:979 ||| NNS
included  ||| S:979 E:988 ||| VBD
in  ||| S:988 E:991 ||| IN
our  ||| S:991 E:995 ||| PRP$
study ||| S:995 E:1000 ||| NN
,  ||| S:1000 E:1002 ||| ,
PDE5I  ||| S:1002 E:1008 ||| CD
use  ||| S:1008 E:1012 ||| NN
was  ||| S:1012 E:1016 ||| VBD
as  ||| S:1016 E:1019 ||| RB
follows ||| S:1019 E:1026 ||| VBZ
:  ||| S:1026 E:1028 ||| :
253  ||| S:1028 E:1032 ||| CD
( ||| S:1032 E:1033 ||| -LRB-
23.4  ||| S:1033 E:1038 ||| NNP
% ||| S:1038 E:1039 ||| NN
)  ||| S:1039 E:1041 ||| -RRB-
non-users ||| S:1041 E:1050 ||| NNP
,  ||| S:1050 E:1052 ||| ,
475  ||| S:1052 E:1056 ||| CD
( ||| S:1056 E:1057 ||| -LRB-
43.9  ||| S:1057 E:1062 ||| NNP
% ||| S:1062 E:1063 ||| NN
)  ||| S:1063 E:1065 ||| -RRB-
on-demand  ||| S:1065 E:1075 ||| JJ
users ||| S:1075 E:1080 ||| NNS
,  ||| S:1080 E:1082 ||| ,
and  ||| S:1082 E:1086 ||| CC
354  ||| S:1086 E:1090 ||| CD
( ||| S:1090 E:1091 ||| -LRB-
32.7  ||| S:1091 E:1096 ||| NNP
% ||| S:1096 E:1097 ||| NN
)  ||| S:1097 E:1099 ||| -RRB-
in  ||| S:1099 E:1102 ||| IN
the  ||| S:1102 E:1106 ||| DT
rehabilitation ||| S:1106 E:1120 ||| NN
.  ||| S:1120 E:1122 ||| .
Multivariate  ||| S:1122 E:1135 ||| JJ
analysis  ||| S:1135 E:1144 ||| NN
showed  ||| S:1144 E:1151 ||| VBD
that  ||| S:1151 E:1156 ||| IN
PDE5I  ||| S:1156 E:1162 ||| CD
use  ||| S:1162 E:1166 ||| NN
was  ||| S:1166 E:1170 ||| VBD
not  ||| S:1170 E:1174 ||| RB
a  ||| S:1174 E:1176 ||| DT
significant  ||| S:1176 E:1188 ||| JJ
factor  ||| S:1188 E:1195 ||| NN
with  ||| S:1195 E:1200 ||| IN
regard  ||| S:1200 E:1207 ||| NN
to  ||| S:1207 E:1210 ||| TO
BCR  ||| S:1210 E:1214 ||| NNP
risk  ||| S:1214 E:1219 ||| NN
[ ||| S:1219 E:1220 ||| -LRB-
hazard  ||| S:1220 E:1227 ||| NN
ratio  ||| S:1227 E:1233 ||| NN
1.47  ||| S:1233 E:1238 ||| CD
( ||| S:1238 E:1239 ||| -LRB-
0.765-2.826 ||| S:1239 E:1250 ||| NNP
) ||| S:1250 E:1251 ||| -RRB-
;  ||| S:1251 E:1253 ||| :
p = 0.248 ||| S:1253 E:1262 ||| CD
) ||| S:1262 E:1263 ||| -RRB-
.  ||| S:1263 E:1265 ||| .
Among  ||| S:1265 E:1271 ||| IN
the  ||| S:1271 E:1275 ||| DT
PDE5I  ||| S:1275 E:1281 ||| CD
users ||| S:1281 E:1286 ||| NNS
,  ||| S:1286 E:1288 ||| ,
a  ||| S:1288 E:1290 ||| DT
strategy  ||| S:1290 E:1299 ||| NN
for  ||| S:1299 E:1303 ||| IN
PDE5I  ||| S:1303 E:1309 ||| CD
use  ||| S:1309 E:1313 ||| NN
( ||| S:1313 E:1314 ||| -LRB-
on-demand  ||| S:1314 E:1324 ||| FW
vs.  ||| S:1324 E:1328 ||| FW
rehabilitation ||| S:1328 E:1342 ||| FW
) ||| S:1342 E:1343 ||| -RRB-
,  ||| S:1343 E:1345 ||| ,
timing  ||| S:1345 E:1352 ||| NN
of  ||| S:1352 E:1355 ||| IN
initiating  ||| S:1355 E:1366 ||| VBG
PDE5I  ||| S:1366 E:1372 ||| CD
treatment  ||| S:1372 E:1382 ||| NN
following  ||| S:1382 E:1392 ||| VBG
RP ||| S:1392 E:1394 ||| NNP
,  ||| S:1394 E:1396 ||| ,
duration  ||| S:1396 E:1405 ||| NN
of  ||| S:1405 E:1408 ||| IN
PDE5I  ||| S:1408 E:1414 ||| CD
use ||| S:1414 E:1417 ||| NN
,  ||| S:1417 E:1419 ||| ,
and  ||| S:1419 E:1423 ||| CC
type  ||| S:1423 E:1428 ||| NN
of  ||| S:1428 E:1431 ||| IN
PDE5I  ||| S:1431 E:1437 ||| NNP
used  ||| S:1437 E:1442 ||| VBD
were  ||| S:1442 E:1447 ||| VBD
not  ||| S:1447 E:1451 ||| RB
associated  ||| S:1451 E:1462 ||| VBN
with  ||| S:1462 E:1467 ||| IN
an  ||| S:1467 E:1470 ||| DT
increased  ||| S:1470 E:1480 ||| JJ
BCR  ||| S:1480 E:1484 ||| NNP
risk  ||| S:1484 E:1489 ||| NN
in  ||| S:1489 E:1492 ||| IN
multivariate  ||| S:1492 E:1505 ||| JJ
analyses  ||| S:1505 E:1514 ||| NNS
( ||| S:1514 E:1515 ||| -LRB-
p = 0.304 ||| S:1515 E:1524 ||| NNP
,  ||| S:1524 E:1526 ||| ,
p = 0.177 ||| S:1526 E:1535 ||| NNP
,  ||| S:1535 E:1537 ||| ,
p = 0.332 ||| S:1537 E:1546 ||| NNP
,  ||| S:1546 E:1548 ||| ,
and  ||| S:1548 E:1552 ||| CC
p = 0.105 ||| S:1552 E:1561 ||| NNP
,  ||| S:1561 E:1563 ||| ,
respectively ||| S:1563 E:1575 ||| RB
) ||| S:1575 E:1576 ||| -RRB-
.  ||| S:1576 E:1578 ||| .
In  ||| S:1578 E:1581 ||| IN
addition ||| S:1581 E:1589 ||| NN
,  ||| S:1589 E:1591 ||| ,
PDE5I  ||| S:1591 E:1597 ||| CD
use  ||| S:1597 E:1601 ||| NN
was  ||| S:1601 E:1605 ||| VBD
not  ||| S:1605 E:1609 ||| RB
associated  ||| S:1609 E:1620 ||| VBN
with  ||| S:1620 E:1625 ||| IN
an  ||| S:1625 E:1628 ||| DT
increased  ||| S:1628 E:1638 ||| JJ
risk  ||| S:1638 E:1643 ||| NN
of  ||| S:1643 E:1646 ||| IN
BCR  ||| S:1646 E:1650 ||| NNP
among  ||| S:1650 E:1656 ||| IN
478  ||| S:1656 E:1660 ||| CD
matched  ||| S:1660 E:1668 ||| CD
cohorts  ||| S:1668 E:1676 ||| NNS
( ||| S:1676 E:1677 ||| -LRB-
p = 0.672 ||| S:1677 E:1686 ||| NNP
) ||| S:1686 E:1687 ||| -RRB-
.  ||| S:1687 E:1689 ||| .
PDE5I  ||| S:1689 E:1695 ||| NNP
treatment  ||| S:1695 E:1705 ||| NN
following  ||| S:1705 E:1715 ||| VBG
RP  ||| S:1715 E:1718 ||| NNP
was  ||| S:1718 E:1722 ||| VBD
not  ||| S:1722 E:1726 ||| RB
found  ||| S:1726 E:1732 ||| VBN
to  ||| S:1732 E:1735 ||| TO
have  ||| S:1735 E:1740 ||| VB
any  ||| S:1740 E:1744 ||| DT
significant  ||| S:1744 E:1756 ||| JJ
impact  ||| S:1756 E:1763 ||| NN
on  ||| S:1763 E:1766 ||| IN
biochemical  ||| S:1766 E:1778 ||| JJ
outcome  ||| S:1778 E:1786 ||| NN
regardless  ||| S:1786 E:1797 ||| RB
of  ||| S:1797 E:1800 ||| IN
therapeutic  ||| S:1800 E:1812 ||| JJ
strategy ||| S:1812 E:1820 ||| NN
,  ||| S:1820 E:1822 ||| ,
timing ||| S:1822 E:1828 ||| NN
,  ||| S:1828 E:1830 ||| ,
duration ||| S:1830 E:1838 ||| NN
,  ||| S:1838 E:1840 ||| ,
and  ||| S:1840 E:1844 ||| CC
drug  ||| S:1844 E:1849 ||| NN
type ||| S:1849 E:1853 ||| NN
.  ||| S:1853 E:1855 ||| .
Such  ||| S:1855 E:1860 ||| JJ
findings  ||| S:1860 E:1869 ||| NNS
suggest  ||| S:1869 E:1877 ||| VBP
that  ||| S:1877 E:1882 ||| IN
PDE5I  ||| S:1882 E:1888 ||| CD
treatment  ||| S:1888 E:1898 ||| NN
following  ||| S:1898 E:1908 ||| VBG
RP  ||| S:1908 E:1911 ||| NNP
is  ||| S:1911 E:1914 ||| VBZ
oncologically  ||| S:1914 E:1928 ||| JJ
safe ||| S:1928 E:1932 ||| JJ
.  ||| S:1932 E:1934 ||| .
